Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review
Paul Windisch(Kantonsspital Winterthur), Sebastian Adeberg(Goethe University Frankfurt), Daniel R. Zwahlen(Kantonsspital Winterthur), Jürgen Debus(Heidelberg University), Frederik L. Giesel(Düsseldorf University Hospital), Uwe Haberkorn(German Cancer Research Center), Eberhard Scholz(Heidelberg University), Patrick Lugenbiel(Heidelberg University)
Cited by 51
Related Papers
Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
|Journal of Nuclear Medicine|2018|908
Upregulation of K <sub>2P</sub> 3.1 K <sup>+</sup> Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation
|Circulation|2015|195
Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model
|Cardiovascular Research|2011|159
Feasibility Study on Cardiac Arrhythmia Ablation Using High-Energy Heavy Ion Beams
|Scientific Reports|2016|121
Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study
|European Heart Journal|2011|103